General Biotechnology
Biotechnology Venture Investing and Neurodegenerative Medicine: Promise of New Approaches to Cure an Ailing Model
Neurodegenerative diseases are one of the leading public health challenges of the next 50 years. Pharmaceutical therapies have traditionally targeted the later stages of neurodegenerative diseases; however, this strategy – as the recent failures of clinical trials for Alzheimer’s drugs have highlighted – has been unsuccessful. Venture capital has underperformed as well during this time, as many new companies have been unable to maintain growth once they reach the public market and have produced less than desirable returns. As a result, venture capitalists have opted for later-stage financing. Nevertheless, new technologies are being developed to answer the question of how to best address neurodegeneration. New tools of detection will allow for much earlier diagnosis and a much greater chance of discovering and applying effective treatments. Realizing that genetic knowledge is insufficient to produce innovative treatments for neurodegenerative diseases, scientists have begun to apply the genetic knowledge attained towards a future of individualized treatments. As these new tools of detection converge with an increased ability to create very precise individual solutions, the risk of successful future investments should come down and provide the potential for outsized returns that have traditionally governed the venture capital financial model.
General Biotechnology
A Social Media Manifesto
The role of marketing communications is to advance the bottom line and the public good – and not necessarily in that order. Giving back is an integral part of the New Normal. And there has never been a better tool to accomplish this mission than social media.
But healthcare marketing –and particularly of the regulated variety –is between a rock and a hard place. On the one hand, marketers understand the importance and opportunity in social media. It’s where the people are. It’s where the action is. But then there are all those pesky regulatory concerns.
As Walter O’Malley –the man who moved the Brooklyn Dodgers to Los Angeles once commented, “The future is just one damn thing after another.”
General Biotechnology
Biotech in Countries Starting with 'I' – Part 5
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
General Biotechnology
Human cell- and tissue- based products: Progress, promise and regulatory issues
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Human cell- and tissue- based products: Progress, promise and regulatory issues
Go to paperABSTRACT: The field of cell- and tissue-based products is radical…
Human cell- and tissue- based products: Progress, promise and regulatory issues Read Post »
General Biotechnology
Fourth Edition of Building Biotechnology now Available
The fourth edition of Building Biotechnology, the premier biotechnology industry primer, is now available. Building Biotechnology has been adopted by dozens of
Fourth Edition of Building Biotechnology now Available Read Post »
General Biotechnology
Embryo and stem cell research: Views from the USA
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Embryo and stem cell research: Views from the USA
Go to paperABSTRACT: Presents a study that examined the history, ethical debates and religious views rega…
Embryo and stem cell research: Views from the USA Read Post »
General Biotechnology, Guest content
Is the Research Enterprise in Decline? (Part 2)
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
General Biotechnology
Internship opportunities at BiotechBlog.com
With prior BiotechBlog intern Fintan Burke moving on to some exciting new projects, I have time to train a few
General Biotechnology
New book by biotechnology pioneer Ananda Chakrabarty
Ananda Chakrabarty is the holder of the first patent on a genetically-modified organism. Lately he’s turned his sights to a
New book by biotechnology pioneer Ananda Chakrabarty Read Post »